# OnCo record primary-cns-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/primary-cns-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "primary-cns-lymphoma" ;
  schema:name "Primary CNS lymphoma"@en ;
  schema:alternateName "PCNSL"@en ;
  schema:description "Primary CNS lymphoma is a lymphoma confined to the brain, eyes and spinal fluid. Unlike most brain tumours it is chemo-sensitive: high-dose methotrexate-based treatment cures a substantial minority, and consolidation with a stem-cell transplant has replaced whole-brain radiation for the fit."@en ;
  schema:url <https://onco.cc/cancers/primary-cns-lymphoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Primary_central_nervous_system_lymphoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q3246818> ;
  schema:citation <https://doi.org/10.1038/s41375-022-01582-5>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425>, <https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq> ;
  onco:tag "gap-fill", "haematologic", "cns" ;
  onco:related <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/hiv-associated-lymphoma/>, <https://onco.cc/cancers/post-transplant-lymphoproliferative-disorder/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/btk/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd79b/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/thiotepa/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/curis/> ;
  onco:terms <https://onco.cc/terms/blood-brain-barrier/>, <https://onco.cc/terms/cell-of-origin/>, <https://onco.cc/terms/myd88-l265p/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ferreri-leukemia/> ;
  onco:pipeline <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/zamtocabtagene-autoleucel/> ;
  onco:standardOfCare <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/trials/ielsg32/>, <https://onco.cc/trials/ielsg43/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/nivolumab/> .